Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with severe psoriasis: drug trial shows promise

NCT ID NCT03997786

Ongoing Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

First seen Mar 25, 2026 · Last updated May 01, 2026 · Updated 4 times

Summary

This study tests a drug called tildrakizumab in children aged 6 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it safely reduces skin symptoms like redness and scaling. Participants receive the drug or a placebo, and the study tracks how well it works over time. Since psoriasis is a chronic condition, treatment is meant to control it long-term, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site 1

    Fountain Valley, California, 92708, United States

  • Site 14

    Spokane, Washington, 99202, United States

  • Site 2

    Thousand Oaks, California, 91320, United States

  • Site 20

    Miami, Florida, 33126, United States

  • Site 39

    Wroclaw, 51-503, Poland

  • Site 41

    Barcelona, 08041, Spain

  • Site 47

    Las Palmas de Gran Canaria, 35019, Spain

  • Site 50

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Site 51

    Katowice, 40-611, Poland

  • Site 52

    Szczecin, 70-332, Poland

  • Site 53

    Warsaw, 02-507, Poland

  • Site 54

    Lodz, 90-265, Poland

  • Site 56

    Lodz, 90-436, Poland

  • Site 57

    Bialystok, 15-453, Poland

  • Site 58

    Lublin, 20-573, Poland

  • Site 59

    Sosnowiec, 41-200, Poland

  • Site 61

    Debrecen, H-4032, Hungary

  • Site 62

    Budapest, H-1036, Hungary

  • Site 63

    Budapest, H-1033, Hungary

  • Site 64

    Kaposvár, H-7400, Hungary

  • Site 7

    Miami, Florida, 33173, United States

  • Site 71

    Lucknow, 226005, India

  • Site 74

    Surat, 395002, India

  • Site 79

    Ahmedabad, 380009, India

  • Site 90

    Trnava, 91775, Slovakia

  • Site 91

    Svidník, 8901, Slovakia

  • Site 92

    Bardejov, 8501, Slovakia

Conditions

Explore the condition pages connected to this study.

MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS